Regulatory Inspection Outcome

Wanbury Limited's API manufacturing facility located at Tanuku, Andhra Pradesh, has successfully completed a three-day cGMP (current Good Manufacturing Practices) inspection conducted by the Ministry of Food and Drug Safety (MFDS), Republic of Korea. The inspection resulted in zero observations, indicating full compliance with applicable cGMP standards.

Inspection Details

The inspection was conducted by two senior inspectors from South Korea's MFDS, which is described as a leading international pharmaceutical regulatory authority. The inspection covered the facility's compliance with applicable Good Manufacturing Practices standards.

Historical Context

This achievement follows the successful completion of a previous South Korea MFDS cGMP inspection at the Company's Patalganga manufacturing facility in April 2026, which was also concluded with zero observations.

Company Commitment and Focus

The consecutive achievements reflect Wanbury Limited's strong commitment to quality, regulatory compliance and operational excellence. The Company states it remains focused on continuously strengthening its quality systems and enhancing manufacturing standards in line with evolving international regulatory requirements and global cGMP expectations.

Regulatory Jurisdictions

The document lists multiple regulatory jurisdictions including: US, Europe, Brazil, Korea, India, Mexico, Canada, China, and WHO GMP, indicating the company's regulatory compliance scope.

Disclosure Context

This announcement is made pursuant to Regulation 30 of SEBI LODR (Listing Obligations and Disclosure Requirements).